MERSANA THERAPEUTICS INC (MRSN)
US59045L1061 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to MRSN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.85. This target is 103.22% above the current price.
MRSN was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about MRSN.
In the previous month the buy percentage consensus was at a similar level.
MRSN was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-19 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-29 | Guggenheim | Upgrade | Neutral -> Buy |
| 2024-02-29 | Wedbush | Upgrade | Neutral -> Outperform |
| 2024-02-29 | Truist Securities | Upgrade | Hold -> Buy |
| 2024-02-29 | Baird | Maintains | Neutral -> Neutral |
| 2023-12-04 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-07-28 | Baird | Downgrade | Outperform -> Neutral |
| 2023-07-28 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-07-27 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-07-27 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-06-16 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-06-16 | Citigroup | Maintains | Buy -> Buy |
| 2023-06-15 | Guggenheim | Initiate | Buy |
| 2023-05-11 | Citigroup | Maintains | Buy |
| 2023-03-16 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2022-11-21 | Truist Securities | Initiate | Buy |
| 2022-08-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-09 | Baird | Maintains | Outperform |
| 2022-05-09 | SVB Leerink | Maintains | Outperform |
| 2022-02-18 | SVB Leerink | Maintains | Outperform |
| 2021-08-30 | HC Wainwright & Co. | Initiate | Buy |
| 2021-03-31 | Credit Suisse | Initiate | Neutral |